Image beyond bone – into oncology, cardiovascular and pulmonary diseases, and much more, with the Quantum GX2 microCT imaging system. With the Quantum GX2, flexibility is key. Combining the ability to perform high speed, low dose scans, ideal for longitudinal studies, across multiple species (mice, rats, rabbits) with high resolution ex vivo scanning, the Quantum GX2 microCT imaging system offers the flexibility and performance you need to not just image, but further understand your disease models.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
The Quantum GX2 microCT scanner is a true multispecies preclinical imaging system, offering the flexibility to enable longitudinal in vivo imaging as well as ex vivo sample scanning. With a 163mm imaging bore, an entire rabbit can be placed inside the scanner for in vivo scanning, while the 18mm FOV allows for high resolution scanning of ex vivo samples. Combined with PerkinElmer's 3-dimensional optical imaging systems, and automated bone analysis software (AccuCT™), the Quantum GX2 microCT imaging system provides maximal flexibility and function. Whether your research focus is oncology, cardiovascular disease, orthopedics or pulmonary disease, the Quantum GX2 is versatile enough to deliver the results you need.
Combine the Quantum GX2 microCT imaging with PerkinElmer's other in vivo imaging modalities (optical and PET) to gain greater insight into disease progression and treatment response non-invasively.
For additional publications, please visit Google Scholar.
|Imaging Modality||microCT Imaging|
|Product Brand Name||Quantum|
Blood vessel mechanics and function are important aspects of cardiovascular research. Arterial changes have been associated with several pathophysiological conditions, disease states and treatment. Structural components of the arterial vessel wall, smooth vasculature tone, and transmural distending pressure are the primary determinants of vascular wall mechanical properties.
Pulmonary Arterial Hypertension (PAH) is a life-threatening disease that affects the arteries in the lungs and the right side of the heart. It is characterized by an increase in pulmonary arterial pressure leading to right ventricular (RV) hypertrophy, heart failure, and death.
Small animal models are often used in experimental PAH research due to their similarities to human cardiovascular physiology. MRI and Ultrasound are established tools in evaluating RV function and physiology but each can present certain challenges including complex acquisition techniques, long imaging times, high imaging costs and accessibility. Conversely, microCT offers superior special resolution, fast acquisition times, 4D imaging, and ease-of-use.
Read this application note highlighting how researchers used the Quantum GX microCT system to quantify distensibility measurements in a rodent model using contrast-enhanced retrospectively gated computed tomography imaging.
X-ray CT imaging is commonly used for skeletal imaging as bones are densely mineralized tissues with excellent x-ray attenuation properties. In contrast, soft, less dense tissues often prove to be challenging to image due to their lack of sufficient tissue density. Soft tissues such as muscle, blood vessels and internal organs share similar x-ray attenuation characteristics and are not distinguishable under typical CT settings. In order to introduce density that would improve soft tissue contrast, several contrast agents have been developed for use in clinical and preclinical settings. This application note outlines the use of iodine and nanoparticle-based contrast agents for imaging soft tissues and vasculature in various organs using the Quantum GX to gain further insights into disease and therapeutic response.
Osteoarthritis (OA) is the most common form of arthritis and affects a considerable portion of the elderly population. In the U.S., it is estimated that more than 630 million people worldwide have this chronic condition, generally in the knees. OA occurs when the cartilage that cushions the ends of bones within the joints gradually deteriorates, causing synovitis and joint deformation.
The goal of OA research is to identify new therapeutic strategies that could prevent, reduce, halt progression, or repair the existing damage to the joint. Non-invasive in vivo imaging such as microCT is the standard modality for bone research due to its ability to obtain high-resolution images at an x-ray dose low enough as not to harm the animal. This makes microCT ideal for monitoring disease progression and response to treatments in the same animal over time. However, microCT data visualization and analysis can be cumbersome and time consuming. In this application note, we compared standard microCT software and advanced bone software to investigate bone erosion in an OA rat model.
Pulmonary Arterial Hypertension (PAH) is a life-threatening disease that affects the arteries in the lungs and the right side of the heart. Small animal models are often used in experimental PAH research due to their similarities to human cardiovascular physiology. MRI and microPET are established tools in evaluating RV function and physiology but both can present certain challenges including complex acquisition techniques, high imaging costs and accessibility. Conversely, microCT offers superior resolution, rapid data acquisition, and ease-of-use. Read this editorial and article published in the December issue of Circulation on how researchers report on the first quantitative assessment of RV and left ventricular systolic and diastolic volumes and function in an experimental model of PAH using the Quantum GX2 microCT imaging system.
It’s simple: More information means more understanding,For today’s researchers in oncology, infectious diseases, inflammation, neuroscience, stem cells,and other disciplines, there’s an increasing need for in vivo imaging that enables you to visualize,multiple events simultaneously and to extract the maximum amount of information from each,subject – leading to greater biological understanding.,Multimodal imaging enables a better understanding of disease biology. By utilizing in vivo,optimized bioluminescent and fluorescent agents and radioactive probes, researchers can,measure depth, volume, concentration, and metabolic activity, providing a wealth of information,for untangling the mysteries of disease.,Coregistration allows researchers to overlay images from multiple imaging modalities, providing,more comprehensive insight into the molecular and anatomical features of a model subject.,For example, optical imaging data can be used to identify and quantify tumor burden at,the molecular level and, when integrated with microCT, provides a quantitative 3D view of,anatomical and functional readouts.,At PerkinElmer, we’ve developed industry leading imaging technology for preclinical research.,Our technology integrates 3D optical and PET modalities with microCT to provide a better,understanding of disease. And that means better monitoring of disease progression, earlier,detection of treatment efficacy, and deeper understanding of metabolic changes that take place,throughout disease development.
Like the brain, neuroscience has a multitude of layers. Our broad solutions, innovative technologies, and proven expertise help researchers like you understand neurological diseases so that patients can benefit from better treatments and therapies.
Lung cancer is the leading cause of cancer death worldwide with Small Cell Lung Cancer (SCLC), an aggressive form with a typical survival rate of 10-12 months, accounting for roughly 14% of all lung cancers. The primary chemotherapy treatment regimen for SCLC is etoposide plus a platinum-based drug such as cisplatin or carboplatin. Although patients initially respond well to this treatment, tumors often develop resistance to this drug protocol. Poor prognostic factors for this type of lung cancer coupled with the fact that the chemotherapy regimen has not changed substantially in 40 years highlight the urgent need to develop new therapeutic approaches to treating SCLC.
Read this case study to learn how Dr. Trudy Oliver and colleagues at the Huntsman Cancer Research Center in Salt Lake City, Utah (USA) used a Genetically Engineered Mouse Model (GEMM) and microCT imaging using the Quantum GX2 system to study and quantify tumor growth, progression, and evaluate treatment approaches in MYC-driven SCLC tumors.
Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.
Emphysema is a form of chronic obstructive pulmonary disease (COPD) most often association with smoking. It is a leading cause of death worldwide and is characterized by irreversible and severe destruction of the alveolar lung sacs. Small animal models are critical to understanding lung disease, however despite the severe morphological changes within the lung, imaging in small animal models can be challenging.
View this poster, presented at the 19th Fraunhofer Seminar "Models of Lung Disease“ in Hannover, Germany, where scientists from Boehringer Ingelheim and PerkinElmer developed a method using the Quantum microCT imaging system for rapid assessment of lung compliance and resistance in an emphysema mouse model. When used in conjunction with a small animal ventilator this methodology can be used as a non-destructive and cost-effective tool for rapid and longitudinal assessment of pathophysiological changes in the lung. This method can be further extended towards characterization of other models of lung disease and for evaluation of novel preventive and therapeutic strategies.
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.